BRIEF-Dogwood Therapeutics Announces Commencement Of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2B Long Term Extension Study

Dogwood Therapeutics Inc

DWTX

0.00

May 18 (Reuters) - Dogwood Therapeutics Inc DWTX.O:

DOGWOOD THERAPEUTICS ANNOUNCES COMMENCEMENT OF HALNEURON® CHEMOTHERAPY INDUCED NEUROPATHIC PAIN PHASE 2B LONG TERM EXTENSION STUDY
DOGWOOD THERAPEUTICS INC - EXTENSION TRIAL DATA TO SUPPORT FDA SUBMISSION FOR PHASE 3 PROGRAM IN H1 2027
DOGWOOD THERAPEUTICS INC - TOP-LINE RESULTS FROM DOUBLE-BLINDED CINP STUDY EXPECTED IN FALL 2026

Source text: ID:nGNX7v8kq

Further company coverage: DWTX.O

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.